メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
岡澤 成祐
助教, 博士（医学） 富山大学 2013年3月
内科学（第一）講座
https://sandbox.orcid.org/0000-0002-2592-7131
h-index
443
被引用数
12
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2009
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(34)
類似のプロファイル
(6)
フィンガープリント
Seisuke Okazawaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Adverse Effects
25%
Appetite Loss
13%
Asthma
14%
Body Mass Index
12%
C-ratio
11%
Chemotherapy
30%
Chemotherapy-induced
11%
Clinical Course
21%
Clinical Parameters
17%
Comorbidity
12%
Confidence Interval
11%
Egfr
17%
EGFR Status
12%
Elderly Patients
22%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
17%
Gefitinib
12%
Immune Checkpoint Inhibitor Therapy
36%
Immune Checkpoint Inhibitors
44%
Irinotecan
11%
Ischemic Heart Disease
13%
Lactate Dehydrogenase
15%
Leptomeningeal Carcinomatosis
12%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
19%
Lung Adenocarcinoma
43%
Lung Cancer
84%
Monotherapy
40%
Mouse Model of Asthma
11%
Nivolumab
13%
Non-small Cell Lung Cancer (NSCLC)
100%
Non-squamous
15%
Older Men
16%
Overall Survival
12%
Patient Characteristics
16%
Pembrolizumab
11%
Pemetrexed
12%
Performance Status
17%
Postoperative Recurrence
12%
Prognostic Factors
24%
Programmed Death-ligand 1 (PD-L1)
15%
Programmed Death-ligand 1 Expression
18%
Progression-free Survival
54%
Right Upper Lobe
12%
Sirtuin 1 (SIRT1)
22%
Small Cell Lung Cancer
38%
Squamous Cell
15%
Systemic Therapy
13%
T790M mutation
12%
Total Adiponectin
11%
Tumor
22%
Young Patients
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
33%
Amrubicin
11%
Asthma
15%
Autoimmune Hemolytic Anemia
5%
Carcinoma
11%
Carnitine
11%
Chemotherapy
51%
Chronic Obstructive Lung Disease
11%
Cisplatin
11%
Creatinine
11%
Cystatin C
11%
Disease
14%
Disease Course
13%
Docetaxel
9%
Epidermal Growth Factor Receptor
45%
Epidermal Growth Factor Receptor Kinase Inhibitor
14%
Fibrosis
9%
Hydrocortisone
11%
Immune Checkpoint Inhibitor
45%
Inflammation
13%
Irinotecan
11%
Ischemic Heart Disease
11%
Lactate Dehydrogenase
18%
Loss of Appetite
11%
Lung Adenocarcinoma
8%
Lung Cancer
35%
Messenger RNA
12%
Minoxidil
8%
Monotherapy
39%
Mouse Model
11%
N [2 [3 (1 piperazinylmethyl)imidazo[2,1 B]thiazol 6 Yl]phenyl] 2 Quinoxalinecarboxamide
11%
Neoplasm
24%
Neurotoxicity
11%
Non Small Cell Lung Cancer
61%
Observational Study
9%
Ovalbumin
11%
Overall Survival
23%
Pembrolizumab
6%
Pemetrexed
11%
Pharmacokinetics
11%
Programmed Death 1 Ligand 1
25%
Progression Free Survival
45%
Radiation Pneumonia
11%
Recurrent Disease
16%
Retrospective Study
42%
Sirtuin 1
11%
Small Cell Lung Cancer
41%
Squamous Cell Lung Carcinoma
11%
Valaciclovir
11%
Wheezing
11%
Medicine and Dentistry
Adverse Event
17%
Afatinib
11%
Amrubicin
11%
Body Mass Index
11%
Carcinoma
11%
Chemotherapy
23%
Chronic Obstructive Pulmonary Disease
11%
Comorbidity
12%
Disease Course
21%
Epidermal Growth Factor Receptor
18%
Erlotinib
11%
Evacuation
11%
Gastroenteritis
11%
Gefitinib
12%
Hamartoma
11%
Hydrocortisone
11%
Immune Checkpoint Inhibitor
51%
Immunotherapy
11%
Lactate Dehydrogenase
12%
Liver Toxicity
11%
Local Therapy
11%
Loss of Appetite
13%
Lung
21%
Lung Adenocarcinoma
43%
Lung Aspergillosis
11%
Lung Cancer
82%
Lung Metastasis
11%
Meningeal Carcinomatosis
12%
Monotherapy
20%
Mouth Squamous Cell Carcinoma
11%
Neoplasm
11%
Nivolumab
13%
Non Small Cell Lung Cancer
53%
Oral Cancer
11%
Overall Survival
11%
Patient Characteristics
12%
Peripheral Blood Mononuclear Cell
11%
Physical Activity
11%
Pneumocystis Pneumonia
11%
Progression Free Survival
24%
Recurrent Disease
16%
Resuscitation
11%
Retrospective Study
30%
Septic Arthritis
11%
Sirtuin1
11%
Small Cell Lung Cancer
17%
Systemic Therapy
13%
T Lymphocyte
11%
T-Helper Cell
14%
Wheeze
11%
